IRIDEX (NASDAQ:IRIX) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Sunday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Trading Down 4.5 %

NASDAQ IRIX opened at $1.69 on Friday. IRIDEX has a 52 week low of $1.27 and a 52 week high of $3.65. The company has a 50 day moving average price of $1.67 and a 200 day moving average price of $2.01. The company has a quick ratio of 0.86, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The firm has a market cap of $28.12 million, a PE ratio of -2.52 and a beta of 0.80.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The business had revenue of $11.58 million for the quarter. During the same quarter in the previous year, the firm posted ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.